COYA Coya Therapeutics Inc
Price (delayed)
$6.54
Market cap
$109.38M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.98
Enterprise value
$71.04M
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities,
Highlights
The company's equity rose by 24% QoQ and by 11% YoY
The company's quick ratio rose by 26% YoY but it fell by 25% QoQ
COYA's net income has shrunk by 86% YoY and by 39% QoQ
COYA's revenue has plunged by 63% from the previous quarter and by 41% YoY
Key stats
What are the main financial stats of COYA
Market
Valuations
Earnings
Shares outstanding
16.72M
Market cap
$109.38M
Enterprise value
$71.04M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.76
Price to sales (P/S)
28.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.99
Revenue
$3.55M
Gross profit
$3.55M
Operating income
-$17.25M
Net income
-$14.88M
EBIT
-$15.6M
EBITDA
-$15.57M
Free cash flow
-$10.29M
Per share
Balance sheet
Liquidity
EPS
-$0.98
EPS diluted
-$0.98
Free cash flow per share
-$0.68
Book value per share
$2.37
Revenue per share
$0.23
TBVPS
$2.91
Total assets
$44.35M
Total liabilities
$4.77M
Debt
$0
Equity
$39.58M
Working capital
$40.48M
Debt to equity
0
Current ratio
11.59
Quick ratio
10.02
Net debt/EBITDA
2.46
Margins
Efficiency
Dividend
EBITDA margin
-438.2%
Gross margin
100%
Net margin
-418.7%
Operating margin
-485.4%
Return on assets
-37.9%
Return on equity
-42.7%
Return on invested capital
-6,359.7%
Return on capital employed
-38.5%
Return on sales
-439%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COYA stock price
How has the Coya Therapeutics stock price performed over time
Intraday
3.65%
1 week
0.46%
1 month
-7.63%
1 year
-34.21%
YTD
14.14%
QTD
1.08%
Financial performance
How have Coya Therapeutics's revenue and profit performed over time
Revenue
$3.55M
Gross profit
$3.55M
Operating income
-$17.25M
Net income
-$14.88M
Gross margin
100%
Net margin
-418.7%
Coya Therapeutics's operating income has plunged by 118% YoY and by 52% from the previous quarter
COYA's net income has shrunk by 86% YoY and by 39% QoQ
COYA's revenue has plunged by 63% from the previous quarter and by 41% YoY
The gross profit has dropped by 63% since the previous quarter and by 41% year-on-year
Growth
What is Coya Therapeutics's growth rate over time
Valuation
What is Coya Therapeutics stock price valuation
P/E
N/A
P/B
2.76
P/S
28.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.99
The EPS has dropped by 51% since the previous quarter and by 24% year-on-year
The company's equity rose by 24% QoQ and by 11% YoY
The P/B is 14% below the last 4 quarters average of 3.1
COYA's revenue has plunged by 63% from the previous quarter and by 41% YoY
COYA's P/S is 60% above its last 4 quarters average of 16.9
Efficiency
How efficient is Coya Therapeutics business performance
The ROA has contracted by 36% from the previous quarter
Coya Therapeutics's return on equity has decreased by 35% QoQ
Dividends
What is COYA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COYA.
Financial health
How did Coya Therapeutics financials performed over time
COYA's current ratio is up by 42% year-on-year but it is down by 24% since the previous quarter
Coya Therapeutics's total liabilities has increased by 35% from the previous quarter but it has decreased by 15% YoY
Coya Therapeutics's debt is 100% less than its equity
The company's equity rose by 24% QoQ and by 11% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.